Sandoz Completes Acquisition of Generic Dermatology Company Fougera for $1.5 Billion - - BioPharm International

ADVERTISEMENT

Sandoz Completes Acquisition of Generic Dermatology Company Fougera for $1.5 Billion



Sandoz announced it has completed the acquisition of Fougera Pharmaceuticals, a maker of generic dermatology products, for $1.525 billion in an all-cash transaction.  According to a company press release, the acquisition will complement Sandoz’s existing pipeline of biosimilars and generic injectables, ophthalmics and antibiotics.  Sandoz plans to use its global reach to expand Fougera’s dermatology portfolio into new markets.

Currently, Fougera Pharmaceuticals employs approximately 700 people across its US sites. It operates two main businesses: Fougera, specializing in dermatology development and manufacturing, with expertise in the area of semi-solid forms such as creams and ointments, and PharmaDerm, a branded specialty pharma business. Fougera will be integrated into Sandoz’s US business based in Princeton, NJ, but will continue to exist as a separate legal entity. Fougera’s site in Melville, NY, will be home to a new center of excellence for generic dermatology development and manufacturing within the global Sandoz network.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Novartis and GSK Trade Assets
April 22, 2014
Lilly to Acquire Novartis Animal Health
April 22, 2014
EMA Warns of Falsified Herceptin Vials
April 16, 2014
Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
Author Guidelines

Click here